RecruitingEarly Phase 1NCT07525635

Aspirin Dosing in Pregnancy

Aspirin Dosing and Platelet Phenotype in Pregnancy

Sponsor

NYU Langone Health

Enrollment

30 participants

Start Date

Apr 27, 2026

Study Type

INTERVENTIONAL

Conditions

Preeclampsia Possible

Summary

The purpose of this study is assess platelet phenotypes based on aspirin dosing in pregnant patients at risk for the development preeclampsia who are taking 81mg twice a day aspirin. Blood samples will be collected approximately 4 weeks after initiation of aspirin to evaluate the platelet phenotype during pregnancy in patients.

Eligibility

Sex: FEMALEMin Age: 18 YearsMax Age: 50 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Aspirin for people with preeclampsia possible. The study is currently recruiting participants at 1 location. People eligible for this study include women aged 18 Years to 50 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGAspirin

81mg twice a day (162mg total)

Locations(1)

NYU Langone Health

New York, New York, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07525635